Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 16/20 | 0.45 |
| ▸ | TNKS | O95271 | 2/20 | 0.41 |
| ▸ | PARP1 | P09874 | 2/20 | 0.41 |
| ▸ | TNKS2 | Q9H2K2 | 2/20 | 0.41 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24968165 | 0.77 | PDE9A (0.39) | BRD4 | |
| SCHEMBL18185706 | 0.75 | PDE1A (0.43) | BRD4 | |
| SCHEMBL13522607 | 0.74 | MAPK1 (0.33) | BRD4 | |
| SCHEMBL1874812 | 0.73 | MEN1 (0.47) | BRD4TNKSPARP1TNKS2PDPK1 | |
| SCHEMBL18185760 | 0.73 | PDE1C (0.49) | — | |
| SCHEMBL24859515 | 0.70 | BRD4 (0.41) | BRD4 | |
| SCHEMBL18519546 | 0.68 | ADORA3 (0.44) | BRD4 | |
| SCHEMBL22828057 | 0.68 | PDE1B (0.36) | TNKSPARP1TNKS2 | |
| SCHEMBL18956004 | 0.68 | BRD4 (0.54) | BRD4PDPK1 | |
| SCHEMBL18185696 | 0.67 | PDE1B (0.54) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119894897-A | Heteroaromatic compounds for the treatment of neurological disorders | 苏文生命科学有限公司 | 2025-04-25 | — | — | CN | disclosed |
| US-12162890-B2 | Heteroaromatic NMDA receptor modulators and uses thereof | NOVARTIS AG (CH) | 2024-12-10 | — | — | US | disclosed |
| WO-2023006013-A1 | NOVEL PARP7 INHIBITOR AND USE THEREOF | 上海齐鲁制药研究中心有限公司 | 2023-02-02 | — | — | WO | disclosed |
| US-20230023543-A1 | HETEROAROMATIC NMDA RECEPTOR MODULATORS AND USES THEREOF | NOVARTIS AG (CH) | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12162890-B2 | Heteroaromatic NMDA receptor modulators and uses thereof | GRIN2C, GRIN2A, GRIN1 | BRD4 1947/4885TNKS 2608/4885PARP1 3415/4885 |
| US-20230023543-A1 | HETEROAROMATIC NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN2C, GRIN2A, GRIN1 | BRD4 1947/4885TNKS 2608/4885PARP1 3415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.